-1760473974116.webp&w=3840&q=75)
Emerging Therapies in the Treatment of Parkinson's Disease
0% Complete
Course Overview
Course Content
Credits
* AMA PRA Category 1™ credits are used by physicians and other groups like PAs and certain nurses. Category 1 credits are accepted by the ACCME, ARDMS, CCI, and Sonography Canada.
Course Details
- Duration
- 1.00 hour
- Released
- Oct 15, 2025
- Last Review
- Oct 15, 2025
- Expires
- Oct 15, 2028
Objectives
Evaluate the evidence, efficacy, and safety profiles of pipeline therapeutics for treating Parkinson’s Disease
Compare the potential clinical benefits and limitations to current standard treatments for Parkinson's disease
Assess the implications of emerging therapies on clinical decision-making and patient management strategies
Target Audience
This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.
Faculty & Disclosure
Faculty
Zoltan Mari, MD, faculty for this educational event is on the speakers bureau for ACADIA Pharmaceuticals and Supernus; Consultant for ACADIA Pharmaceuticals, AbbVie Inc., and Amneal Pharmaceuticals.
This activity was supported by an independent educational grant from Boston Scientific.
Disclosure
None of the planners, or moderators for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing products used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated. Remaining persons in control of content have no relevant financial relationships.
Accreditation
The Clark County Medical Society is accredited by the Utah Medical Association (UMA) to provide continuing medical education for physicians.
The Clark County Medical Society designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.